DBI and depressive disorder: As a final note, it appears important that ACBP/DBI neutralization, which might constitute a novel treatment for obesity and its comorbidities such as type-2 diabetes and non-alcoholic steatohepatitis, has no unwarranted (depression- or anxiety-inducing) effects on mice.